Evommune Licenses EVO570 From Hinova for $30 Million Upfront

• Evommune agreed to license worldwide rights outside Greater China to Hinova Pharmaceuticals’ EVO570, an investigational oral VAV1 degrader.
• The $30 million upfront payment comprises $20 million cash and $10 million in pre-funded warrants to purchase common stock.
• Hinova is eligible for up to approximately $1.1 billion in milestones, with tiered royalties on net sales outside Greater China.
• A Phase 1 trial assessing safety, pharmacokinetics and target engagement is expected to begin imminently.
• The first Phase 2 trial in rheumatoid arthritis is planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104900140) on November 04, 2026, and is solely responsible for the information contained therein.